Bupropion: Nursing Drug Guide, Seizure Risk & Monitoring

Bupropion is available in multiple oral formulations with different release profiles. This guide uses Wellbutrin XL extended-release prescribing information as the primary reference—verify the exact product on the MAR before administration.

Wellbutrin XL (bupropion hydrochloride extended-release) is supplied as 150 mg and 300 mg tablets for once-daily morning dosing. Other marketed brands include Wellbutrin SR, immediate-release Wellbutrin, Zyban (smoking cessation), Aplenzin, and Forfivo XL. Do not substitute XL, SR, or IR products without prescriber and pharmacy approval—bioavailability and seizure risk differ.

Wellbutrin XL is indicated for adults with major depressive disorder (MDD) and for prevention of seasonal affective disorder (SAD) episodes. Nurses also encounter bupropion for smoking cessation under separate product labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine (NDRI) and does not inhibit monoamine oxidase or the reuptake of serotonin. The exact antidepressant mechanism is unknown. Clinically, nurses should expect activating adverse effects (insomnia, agitation, tremor) rather than prominent sedation, and remember bupropion inhibits CYP2D6, which can raise levels of co-prescribed drugs such as sertraline, fluoxetine, venlafaxine, nortriptyline, and metoprolol.

Dosing below reflects Wellbutrin XL labeling. Increase dose gradually to reduce seizure risk. Periodically reassess the need for maintenance treatment.

Seizure risk ceiling: Wellbutrin XL labeling states the dose should not exceed 300 mg once daily. Labeling also notes that seizure risk across bupropion programs can be reduced by limiting total daily dose to 450 mg with gradual titration—verify the specific product maximum on the MAR.

Missed dose: If a dose is missed, do not take an extra tablet to make up for it—take the next dose at the regular time (at least 24 hours apart). Extra bupropion increases seizure risk.

Discontinuation: When stopping Wellbutrin XL 300 mg once daily, decrease to 150 mg once daily before discontinuing per labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Screen for epilepsy or seizure disorder, head injury, CNS tumor, or prior seizure on bupropion—drug is contraindicated with seizure disorder
• Ask about current or prior bulimia or anorexia nervosa (contraindicated—higher seizure incidence)
• Review alcohol, benzodiazepine, barbiturate, or antiepileptic use—avoid abrupt withdrawal of sedatives or alcohol when starting bupropion
• Perform medication reconciliation for duplicate bupropion products (XL + SR + smoking-cessation brand)
• Obtain baseline blood pressure; assess mood and suicidality in young adults
• Check hepatic history and renal function (BMP, eGFR)

Contraindications (Wellbutrin XL)

• Seizure disorder
• Current or prior diagnosis of bulimia or anorexia nervosa
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
• MAOI intended to treat psychiatric disorders—do not use with MAOIs or within 14 days of stopping an MAOI; do not start within 14 days of stopping Wellbutrin XL before starting an MAOI antidepressant
• Known hypersensitivity to bupropion or formulation excipients

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral. Wellbutrin XL: swallow tablets whole in the morning; may take with or without food; allow at least 24 hours between doses.

• Do not crush, cut, chew, or divide Wellbutrin XL—altered release can cause dose dumping and seizures
• If the patient cannot swallow tablets, contact prescriber/pharmacist for an alternative formulation—do not crush XL on the unit without orders
• Tablets may have a characteristic odor—this is normal per patient labeling
• Confirm the MAR shows the correct brand and strength (150 mg vs 300 mg) before administration

• Gradual improvement in depressive symptoms, energy, or interest over weeks—not immediate like anxiolytics
• For SAD prevention, continued adherence through the winter season per prescriber plan
• May notice decreased tobacco craving when used for smoking cessation (separate product labeling)
• Reassess if activation (anxiety disorders, insomnia, agitation) outweighs benefit—may need dose timing adjustment or prescriber review

Escalate immediately for seizures, hypertensive crisis features, emergent suicidality, or allergic reactions.

• Generalized or focal seizure—stop bupropion, seizure first aid per protocol, notify prescriber; do not restart bupropion after a seizure per labeling
• Severe headache, chest pain, or BP markedly elevated after dose increase—possible hypertension related to bupropion
• New or worsening suicidal ideation, self-harm thoughts, or violent agitation—especially in young adults
• Psychosis, hallucinations, paranoia, or mania/hypomania symptoms
• Angioedema, urticaria, anaphylaxis, or severe skin reaction
• Patient reports chewing, splitting, or duplicating bupropion doses

↔On a small screen, swipe or scroll sideways to see the full table.

Frequency data reflect Wellbutrin XL and related bupropion trial labeling unless otherwise noted.

Overdoses up to 30 grams have been reported. Seizure occurred in approximately one third of overdose cases in labeling. Other serious effects include hallucinations, loss of consciousness, mental status changes, sinus tachycardia, ECG changes, clonus, hyperreflexia, fever, muscle rigidity, rhabdomyolysis, hypotension, stupor, coma, and respiratory failure—especially with polypharmacy.

Management

There is no known antidote for bupropion. Provide supportive care with close medical supervision and monitoring. Consider possibility of multiple drug overdose. Contact local poison control or medical toxicology services per facility protocol and local emergency guidance.

• Bupropion vs buspirone—different drug classes; verify generic name on MAR
• Wellbutrin XL vs SR vs IR—once-daily XL is not interchangeable with twice-daily SR without prescriber change
• Bupropion vs Zyban—same active ingredient for smoking cessation; duplicate therapy causes overdose/seizure risk
• 150 mg vs 300 mg tablets—independent double-check during titration week
• “Wellbutrin” PRN plus scheduled XL—common duplicate-therapy trap on admission

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Blood pressure before initiation and periodically during therapy
• Mood, suicidality, sleep, and activation symptoms (agitation, anxiety, insomnia) at each contact during titration
• Signs of seizure; neurologic status if overdose suspected
• Renal and hepatic function when clinically indicated—trend creatinine and eGFR if dose adjustments are needed
• Adherence to swallow-whole instructions and absence of duplicate bupropion therapy

Document

• Formulation (XL vs SR), dose, time, and patient tolerance
• Screening for eating disorder history, seizure history, and sedative/alcohol withdrawal risk
• Suicidality assessments and family/caregiver education provided
• BP values and prescriber notification for hypertension or seizure events

• Swallow Wellbutrin XL whole—do not chew, cut, or crush; if you cannot swallow tablets, tell your care team
• Take in the morning at about the same time each day; if you miss a dose, do not take an extra tablet—wait for the next dose
• Report seizure, severe headache, chest pain, agitation, trouble sleeping, or thoughts of self-harm immediately
• Do not stop alcohol or sedatives abruptly while starting this medicine unless your prescriber directs a supervised plan
• Urine drug tests may falsely show amphetamines—tell testers you take bupropion
• Keep all mental-health follow-up appointments; involve family in monitoring mood changes when appropriate

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for bupropion with a tabbed case panel (MAR, labs, vitals, nursing notes), then priority action, cue recognition SATA, BP trend interpretation, matrix urgency sorting, CYP2D6 interaction judgment, and documentation cloze—recognise seizure and suicidality cues → analyse threshold risks → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.